AR reprograms lipid metabolism through a multi-level complex network (direct, indirect, and pathway intersection) to meet the bioenergetic and biosynthetic needs of prostate cancer cells, which not only drives tumor progression and metastasis, but also leads to the generation of therapeutic resistance (such as castration resistance). The gene discussed is AR; the disease is prostate carcinoma.